Susan Minton

4.3k total citations
41 papers, 2.9k citations indexed

About

Susan Minton is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Susan Minton has authored 41 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 16 papers in Molecular Biology and 9 papers in Cancer Research. Recurrent topics in Susan Minton's work include HER2/EGFR in Cancer Research (6 papers), Tryptophan and brain disorders (6 papers) and Cancer, Stress, Anesthesia, and Immune Response (5 papers). Susan Minton is often cited by papers focused on HER2/EGFR in Cancer Research (6 papers), Tryptophan and brain disorders (6 papers) and Cancer, Stress, Anesthesia, and Immune Response (5 papers). Susan Minton collaborates with scholars based in United States, Canada and United Kingdom. Susan Minton's co-authors include Pamela N. Münster, Daniel M. Sullivan, Roohi Ismail‐Khan, Ji‐Hyun Lee, M. Lacevic, Robert A. Gatenby, Yoonseok Kam, Robert J. Gillies, Richard Jove and Craig A. Beam and has published in prestigious journals such as Nature Genetics, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Susan Minton

40 papers receiving 2.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Susan Minton United States	22	1.4k	1.4k	563	351	348	41	2.9k
Roohi Ismail‐Khan United States	23	898 0.6×	1.1k 0.8×	332 0.6×	702 2.0×	212 0.6×	60	2.4k
Kazunori Ochiai Japan	27	993 0.7×	937 0.7×	349 0.6×	319 0.9×	203 0.6×	105	3.2k
James Campbell United Kingdom	29	2.1k 1.5×	1.2k 0.9×	374 0.7×	313 0.9×	290 0.8×	61	3.3k
A Hönig Germany	27	1.3k 0.9×	660 0.5×	534 0.9×	137 0.4×	192 0.6×	76	2.6k
Rouba Ali‐Fehmi United States	39	1.2k 0.8×	811 0.6×	874 1.6×	464 1.3×	267 0.8×	152	4.2k
Mark Clemons Canada	20	1.1k 0.8×	2.2k 1.6×	628 1.1×	729 2.1×	825 2.4×	29	3.4k
Amanda McCann Ireland	31	2.3k 1.6×	1.2k 0.9×	1.0k 1.8×	388 1.1×	502 1.4×	83	3.7k
Kenneth B. Ain United States	40	1.6k 1.1×	1.5k 1.1×	318 0.6×	307 0.9×	1.2k 3.5×	78	6.9k
Tadao Tanaka Japan	24	2.8k 1.9×	477 0.4×	2.4k 4.2×	272 0.8×	148 0.4×	94	4.2k
Seiji Isonishi Japan	21	798 0.6×	799 0.6×	227 0.4×	227 0.6×	122 0.4×	80	2.2k

Countries citing papers authored by Susan Minton

Since Specialization

Citations

This map shows the geographic impact of Susan Minton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan Minton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan Minton more than expected).

Fields of papers citing papers by Susan Minton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susan Minton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan Minton. The network helps show where Susan Minton may publish in the future.

Co-authorship network of co-authors of Susan Minton

This figure shows the co-authorship network connecting the top 25 collaborators of Susan Minton. A scholar is included among the top collaborators of Susan Minton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susan Minton. Susan Minton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Amin, Manik, Susan Minton, Patricia LoRusso, et al.. (2015). A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors. Investigational New Drugs. 34(1). 84–95. 35 indexed citations

Molife, L. Rhoda, Yan Li, Joanna Vitfell-Rasmussen, et al.. (2014). Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors. Journal of Hematology & Oncology. 7(1). 1–1. 148 indexed citations

Kam, Yoonseok, Tuhin Das, Susan Minton, & Robert A. Gatenby. (2014). Evolutionary Strategy for Systemic Therapy of Metastatic Breast Cancer: Balancing Response with Suppression of Resistance. Women s Health. 10(4). 423–430. 15 indexed citations

Silva, Ariosto S., et al.. (2012). Evolutionary Approaches to Prolong Progression-Free Survival in Breast Cancer. Cancer Research. 72(24). 6362–6370. 111 indexed citations

Ismail‐Khan, Roohi, Weihong Sun, Hatem Soliman, et al.. (2012). An exploratory study to determine if BRCA1 and BRCA2 mutation carriers have higher risk of cardiac toxicity.. Journal of Clinical Oncology. 30(15_suppl). 1585–1585. 2 indexed citations

Bui, Marilyn M., et al.. (2012). HER2-positive male breast cancer with thyroid cancer: an institutional report and review of literature.. PubMed. 42(2). 135–9. 3 indexed citations

Jim, Heather, Brent J. Small, Susan Minton, Michael A. Andrykowski, & Paul B. Jacobsen. (2011). History of Major Depressive Disorder Prospectively Predicts Worse Quality of Life in Women with Breast Cancer. Annals of Behavioral Medicine. 43(3). 402–408. 29 indexed citations

Robert, Nicholas J., Mansoor N. Saleh, Devchand Paul, et al.. (2011). Sunitinib Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel for First-Line Treatment of Patients With Advanced Breast Cancer: A Phase III, Randomized, Open-Label Trial. Clinical Breast Cancer. 11(2). 82–92. 94 indexed citations

Faul, Leigh Anne, Heather Jim, Susan Minton, et al.. (2011). Relationship of Exercise to Quality of Life in Cancer Patients Beginning Chemotherapy. Journal of Pain and Symptom Management. 41(5). 859–869. 20 indexed citations

10.

Kiluk, John V., Marie Catherine Lee, Tammi Meade, et al.. (2011). Male Breast Cancer: Management and Follow-up Recommendations. The Breast Journal. 17(5). 503–509. 50 indexed citations

11.

Münster, Pamela N., Kenneth T. Thurn, Scott Thomas, et al.. (2011). A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. British Journal of Cancer. 104(12). 1828–1835. 315 indexed citations

12.

Eschrich, Steven A., Gregory Bloom, Yihong Ma, et al.. (2011). Necdin, a Negative Growth Regulator, Is a Novel STAT3 Target Gene Down-Regulated in Human Cancer. PLoS ONE. 6(10). e24923–e24923. 17 indexed citations

13.

Moulder, Stacy L., Anthony Neuger, Jimin Choi, et al.. (2008). Phase 2 study of gemcitabine and irinotecan in metastatic breast cancer with correlatives to determine topoisomerase I localization as a predictor of response. Cancer. 113(10). 2646–2654. 15 indexed citations

14.

Münster, Pamela N., Carolyn D. Britten, Monica Mita, et al.. (2007). First Study of the Safety, Tolerability, and Pharmacokinetics of CP-724,714 in Patients with Advanced Malignant Solid HER2-Expressing Tumors. Clinical Cancer Research. 13(4). 1238–1245. 24 indexed citations

15.

Moulder, Stacy, Nikola Valkov, Jana Gump, et al.. (2006). Is cytoplasmic localization of topoisomerase I (topo I) a mechanism of resistance for topo I inhibitors? Results from an NCCN sponsored phase II trial of gemcitabine and irinotecan in metastatic breast cancer.. Cancer Research. 66. 1270–1271. 1 indexed citations

16.

Cox, Charles E., John M. Cox, Laura White, et al.. (2006). Sentinel Node Biopsy Before Neoadjuvant Chemotherapy for Determining Axillary Status and Treatment Prognosis in Locally Advanced Breast Cancer. Annals of Surgical Oncology. 13(4). 483–490. 47 indexed citations

17.

Minton, Susan, Charles Cox, Tammy Bowman, et al.. (2006). Activation of Stat3 in Primary Tumors from High-Risk Breast Cancer Patients Is Associated with Elevated Levels of Activated Src and Survivin Expression. Clinical Cancer Research. 12(1). 20–28. 205 indexed citations

18.

Weitzner, Michael A., et al.. (2002). A Pilot Trial of Paroxetine for the Treatment of Hot Flashes and Associated Symptoms in Women with Breast Cancer. Journal of Pain and Symptom Management. 23(4). 337–345. 87 indexed citations

19.

Minton, Susan. (2000). CHEMOPREVENTION OF BREAST CANCER IN THE OLDER PATIENT. Hematology/Oncology Clinics of North America. 14(1). 113–130. 8 indexed citations

20.

Sutphen, Rebecca, et al.. (1999). Severe Lhermitte-Duclos disease with unique germline mutation of PTEN. American Journal of Medical Genetics. 82(4). 290–293. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact